BAT1706 · Avzivi

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Glioblastoma, Renal Cell Carcinoma, Ovarian Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
US
  • Bevacizumab biosimilar referencing Avastin (Bio-Thera; commercialized by Sandoz)
Product first approved 2023Outside this platform's coverageFDA label
EU
  • Avzivi: bevacizumab biosimilar used with other cancer medicines (colorectal, breast, lung, kidney, ovarian, cervical cancer)
Product first approved 2024EMA
CN
  • Bevacizumab biosimilar, China trade name Pobevcy: advanced, metastatic or recurrent NSCLC, metastatic colorectal cancer and other indications (company annual disclosure)
Product first approved 2021paper.cnstock.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT04164199 · BeOne Medicines
2019-12-19 – 2026-05-23 · Advanced Malignancies
What this study did
Phase 2 (1)
Other / comorbidity
NCT04948697 · BeiGene
2021-08-20 – 2024-02-01 · Advanced Hepatocellular Carcinoma
What this study did
Phase 1 (2)
Non-Small Cell Lung Cancer
NCT03030430 · Bio-Thera Solutions
2016-03-15 – 2017-06-28 · NSCLC
What this study did
Other / comorbidity
NCT05865574 · Bio-Thera Solutions
2023-06-15 – 2024-01-03 · Healthy Men
What this study did

Competitive landscape

This mechanism is crowded: 38 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Cervical Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
BAT1706 (Avzivi): this drugApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eylea)
Approved(overall)
Protein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Aflibercept-Abzv (Enzeevu)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Ayyh (Pavblu)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Aflibercept-Boav (Eydenzelt)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Brolucizumab-Dbll
Approved(overall)
Antibody fragmentVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Lucentis)
Approved(overall)
Antibody fragmentVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Eqrn (Cimerli)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Hkdz (Ranluspec)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Nuna (Byooviz)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)ApprovedAntibody–drug conjugateTissue Factor (TF)Partial signal
NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7)
NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT5906
Phase 3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CKD-701 (Lucenbies)
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
HLX04-O
Phase 3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ximluci)
Phase 3(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Surabgene Lomparvovec
Phase 3(overall)
Gene therapy / editingVEGF-A
Weak signal(overall)
No reviewed efficacy summary in this indication
Sutantatug EnvedotinPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Tarcocimab Tedromer
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
MW02
Phase 2/3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
ALE.P02
Phase 1/2(overall)
Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rimmyrah)
Phase 1(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Afiveg)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Eyluxvi)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Mynzepli)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Vgenfli)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab (Ranivisio)
—(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab (Rexatilux)
—(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Telbermin
Discontinued
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.